This is a routine conference presentation announcement with no new clinical data or regulatory catalyst. Monitor for any material updates from the CHEST 2026 presentation or the ongoing longitudinal clinical study for CyPath Lung, but no immediate trading catalyst is present.
Price Chart
Executive Summary
bioAffinity Technologies filed an 8-K announcing a Learning Theater presentation at CHEST 2026 on October 21, 2026, highlighting CyPath Lung's role in lung cancer risk stratification and preliminary research data on a new investigational test for asthma and COPD. The filing is a routine conference presentation announcement with no financial data, no regulatory milestone, and no material impact on the company's fundamentals.
Key Facts
- bioAffinity will sponsor a Learning Theater presentation at CHEST 2026 on October 21, 2026.
- Presentation will discuss CyPath Lung for lung cancer risk stratification and managing pulmonary nodules.
- Preliminary research data on a new investigational test for asthma and COPD-related lung inflammation will be discussed.
- The company's Medical and Scientific Advisory Board will convene in conjunction with CHEST 2026.
- CyPath Lung is marketed as a Laboratory Developed Test (LDT) and is not a sole diagnostic tool.
- The asthma/COPD test is an investigational research program and is not available for clinical use.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- No new clinical data or regulatory milestones were announced; the filing is purely promotional.
- The asthma/COPD test is early-stage investigational and may never reach commercialization.
- CyPath Lung is an LDT with limited reimbursement and competitive pressures from blood-based liquid biopsy alternatives.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-047168 |
| Exhibit: ex99-1.htm | 0001493152-26-047168 |
| Document: 0001493152-26-047168-index-headers.html | 0001493152-26-047168 |
| Document: 0001493152-26-047168-index.html | 0001493152-26-047168 |
| Document: 0001493152-26-047168.txt | 0001493152-26-047168 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | DEF 14A | $2.81 | awaiting T+1 | — | $2.99 (+6.58%) |
Oct 15, 2026 12d ago | 8-K | $3.96 $3.73 | ▼ −5.81% | ▼ −4.70% | $2.99 (−24.37%) |
Oct 13, 2026 14d ago | 8-K | $3.63 $3.56 | ▼ −1.79% | ▼ −0.71% | $2.99 (−17.38%) |
Oct 9, 2026 17d ago | 8-K | $3.90 $3.63 | ▲ +7.05% | ▲ +7.04% | $2.99 (+23.21%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 $3.90 | ▲ +17.46% | ▲ +17.40% | $2.99 (+36.61%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 $3.90 | ▼ −17.46% | ▼ −17.40% | $2.99 (−36.61%) |
Oct 8, 2026 19d ago | 8-K | $5.64 $4.73 | ▼ −16.22% | ▼ −16.82% | $2.99 (−46.90%) |
Oct 6, 2026 21d ago | 8-K | $6.06 $6.16 | ▲ +1.65% | ▲ +1.89% | $2.99 (−50.58%) |
Sep 30, 2026 27d ago | 8-K | $6.56 $6.15 | ▼ −6.33% | ▼ −6.50% | $2.99 (−54.34%) |
Sep 22, 2026 5w ago | 8-K | $8.56 $7.94 | ▼ −7.19% | ▼ −6.47% | $2.99 (−64.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers